Two stocks in Healthcare
AbbVie vs Danaher: profit, growth, debt and price compared
AbbVie is stronger on 4 of 6 figures: sales growth, price for its expected profit, dividend and price trend. Danaher is stronger on 2: profit margin and analysts' view.
Save both stocks to your watchlist and revisit their latest fundamentals.
| AbbVieABBV | DanaherDHR | |
|---|---|---|
| Net margin | 15.7% | Stronger: 16.9% |
| Revenue growth, past year | Stronger: +10.32% | +8.28% |
| Debt to equity | — | 51.8% |
| Forward P/E | Stronger: 17.6× | 24.5× |
| Dividend yield | Stronger: 2.42% | 0.71% |
| Analysts | Buy · 26 | Stronger: Strong buy · 21 |
| From its 200-day average | Stronger: +15.5% | +9.3% |
Share price over the past year
- AbbVie+22.3%
- Danaher+1.4%
18 Nov 202518 Nov 2026
AbbVie or Danaher: which is stronger?
- DHR
Which is more profitable?
Danaher keeps more of each sale as profit: 16.9% against 15.7%.
- ABBV
Which is growing its sales faster?
AbbVie is growing its sales faster: +10.32% over the past year, against +8.28%.
- ABBV
Which costs less for the profit it is expected to make?
AbbVie costs less for the profit it is expected to make: 17.6× its forward earnings, against 24.5×.
- ABBV
Which pays more in dividends?
AbbVie pays more back in dividends for what a share costs: 2.42% a year, against 0.71%.
- DHR
Which do analysts rate higher?
Analysts are warmer on Danaher: Strong buy, against Buy for AbbVie.
- ABBV
Which is in the stronger price trend?
AbbVie's price is in the stronger trend: 15.5% above its 200-day average, against 9.3% above.
What each company does
ABBVAbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Reports results on 3 February 2027
DHRDanaher
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
Reports results on 27 January 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.